Pemetrexed Patent Expiration
Pemetrexed was first introduced by Eagle Pharmaceuticals Inc
Pemetrexed Patents
Given below is the list of patents protecting Pemetrexed, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Pemfexy | US11793813 | Pemetrexed formulations | Feb 19, 2036 | Eagle Pharms |
| Pemfexy | US12115164 | Pemetrexed Formulations | Feb 19, 2036 | Eagle Pharms |
| Pemfexy | US9604990 | Crystalline forms of pemetrexed diacid and manufacturing processes therefor | Oct 28, 2035 | Eagle Pharms |
| Pemfexy | US7772209 | Antifolate combination therapies |
May 24, 2022
(Expired) | Eagle Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Pemetrexed's patents.
Latest Legal Activities on Pemetrexed's Patents
Given below is the list recent legal activities going on the following patents of Pemetrexed.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 27 Jan, 2025 | US11147817 |
| Patent Issue Date Used in PTA Calculation Critical
| 19 Oct, 2021 | US11147817 |
| Recordation of Patent Grant Mailed Critical
| 19 Oct, 2021 | US11147817 |
| Email Notification Critical
| 30 Sep, 2021 | US11147817 |
| Issue Notification Mailed Critical
| 29 Sep, 2021 | US11147817 |
| Application Is Considered Ready for Issue Critical
| 22 Sep, 2021 | US11147817 |
| Dispatch to FDC | 22 Sep, 2021 | US11147817 |
| Issue Fee Payment Verified Critical
| 20 Sep, 2021 | US11147817 |
| Issue Fee Payment Received Critical
| 20 Sep, 2021 | US11147817 |
| Electronic Review Critical
| 01 Jul, 2021 | US11147817 |
Pemetrexed's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Pemetrexed:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
